Patients with immunotherapy-resistant bladder cancer who received a novel combination treatment demonstrated improved response to treatment, according to a recent study published in Nature Medicine.
Menu
Browsing: Clinical Breakthroughs
Multilevel care interventions improved clinician–documented advanced care planning compared with a clinician-level intervention alone for patients with genitourinary cancer, according to recent findings published in JAMA Oncology.
People with irregular heartbeats taking a common blood pressure drug may be at greater risk of serious bleeding, according to a study recently published in JAMA.
Investigators have discovered that using a novel drug agonist to target the STING pathway in preclinical models of glioblastoma reprogrammed previously suppressed immune responses, according to recent findings published in the Journal of Clinical Investigation.
Combining two cancer drugs may be a promising treatment for advanced metastatic breast cancer, according to the results of a clinical trial published in the Journal of Clinical Oncology.
Patients with obstructive hypertrophic cardiomyopathy who received a new drug demonstrated improved oxygen uptake and exercise tolerance, according to a study published in the New England Journal of Medicine.
Northwestern University scientists have developed a novel antioxidant biomaterial that someday could provide much-needed relief to people living with chronic pancreatitis, according to a new study published in Science Advances.
Northwestern Medicine scientists have used ultrasound technology to penetrate the blood-brain barrier and provide a small dose of a chemotherapy and immunotherapy, a major advance for the treatment of this deadly cancer.
Nudges from an electronic health record system reminding physicians to prescribe hypertension drugs to patients with chronic kidney disease led to improved blood pressure management, according to a clinical trial published in JAMA Internal Medicine.
Patients with metastatic urothelial cancer and increased expression of the NECTIN4 gene had a dramatically better response to antibody treatment than patients with reduced gene expression, according to recent findings published in the Journal of Clinical Oncology.